Realtime | Geld | Brief | Zeit |
---|---|---|---|
0,915 | 0,985 | 15:20 | |
0,915 | 0,980 | 15:22 |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
GRAND PHARMACEUTICAL GROUP Aktie jetzt für 0€ handeln | |||||
08.09. | Sirtex Medical Inc.: Sirtex Receives Expanded CE Mark Approval for SIR-Spheres Y-90 Resin Microspheres | 229 | PR Newswire | Broadened indication increases access to liver cancer treatment across Europe and CE-marked territories.
WOBURN, Mass., Sept. 8, 2025 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading... ► Artikel lesen | |
08.09. | GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: NEW INDICATION OF THE GROUP'S GLOBALLY INNOVATIVE RADIOACTIVE PRODUCT SIR-SPHERES Y-90 RESIN MICROSPHERE ... | 2 | HKEx | ||
27.08. | GRAND PHARMA (00512): CONTINUING CONNECTED TRANSACTION | - | HKEx | ||
19.08. | GRAND PHARMA (00512): 2025 INTERIM RESULTS ANNOUNCEMENT | - | HKEx | ||
05.08. | GRAND PHARMA (00512): DATE OF BOARD MEETING | 1 | HKEx | ||
28.07. | GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: RESTRUCTURING OF THE SHAREHOLDING IN THE COMPANY BY THE CONTROLLING SHAREHOLDER GROUP | 2 | HKEx | ||
22.07. | GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: THE APPLICATION FOR THE GROUP'S GLOBAL INNOVATIVE RDC TLX591 TO JOIN AN INTERNATIONAL MULTICENTER PHASE ... | 1 | HKEx | ||
17.07. | GRAND PHARMA (00512): SUPPLEMENTAL ANNOUNCEMENT TO CONTINUING CONNECTED TRANSACTIONS: BUSINESS COLLABORATION AGREEMENT | 1 | HKEx | ||
17.07. | GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: THE WORLD'S FIRST NASAL SPRAY PRODUCT OF THE GROUP FOR THE TREATMENT OF DRY EYE DISEASE, OC-01, ACHIEVES ... | 2 | HKEx | ||
07.07. | SIR-Spheres® Y-90 Harz-Mikrosphären von Sirtex Medical erhalten FDA-Zulassung für die Behandlung des inoperablen Leberzellkarzinoms | 363 | news aktuell | Woburn, Massachusetts (ots/PRNewswire) - Erweiterte Indikation macht SIR-Spheres® zur ersten und einzigen Radioembolisationstherapie in den USA, die sowohl zur Behandlung des inoperablen Leberzellkarzinoms... ► Artikel lesen | |
07.07. | Sirtex Medical Inc.: Sirtex Medical's SIR-Spheres Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable Hepatocellular Carcinoma | 243 | PR Newswire | Expanded indication makes SIR-Spheres® the first and only radioembolization therapy in the U.S. approved to treat both unresectable hepatocellular carcinoma and metastatic colorectal cancer
WOBURN... ► Artikel lesen | |
07.07. | GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: A NEW INDICATION OF THE GROUP'S GLOBALLY INNOVATIVE RADIOACTIVE PRODUCT SIR-SPHERES Y-90 RESIN MICROSPHERE ... | 2 | HKEx | ||
04.06. | GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: THE GROUP'S GLOBAL INNOVATIVE OPHTHALMIC DRUG CBT-001 COMPLETES THE ENROLLMENT OF ALL PATIENTS IN THE INTERNATIONAL ... | 3 | HKEx | ||
12.05. | GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: THE PHASE III STUDY IN CHINA OF THE GROUP'S GLOBAL INNOVATIVE RDC TLX591-CDX COMPLETES PATIENT ENROLLMENT ... | 2 | HKEx | ||
07.05. | GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: THE APPLICATION FOR THE GROUP'S GLOBAL INNOVATIVE RDC TLX591 TO JOIN INTERNATIONAL MULTICENTER PHASE III ... | - | HKEx | ||
07.05. | Grand Pharmaceutical Group Limited: The world's first: Grand Pharma's global innovative product STC3141 successfully reached the clinical endpoint in the Phase II clinical study in China | 414 | PR Newswire | The results showed that the SOFA scores of the drug treatment groups on the 7th day were significantly lower than those of the baseline, especially in the high-dose group, where the decrease... ► Artikel lesen | |
06.05. | GRAND PHARMA (00512): CLARIFICATION ON CHINESE VERSION OF VOLUNTARY ANNOUNCEMENT: THE PHASE II CLINICAL STUDY IN CHINA OF THE GROUP'S GLOBAL INNOVATIVE ... | - | HKEx | ||
06.05. | GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: THE PHASE II CLINICAL STUDY IN CHINA OF THE GROUP'S GLOBAL INNOVATIVE PRODUCT STC3141 SUCCESSFULLY REACHED ... | - | HKEx | ||
25.04. | GRAND PHARMA (00512): CONTINUING CONNECTED TRANSACTIONS: BUSINESS COLLABORATION AGREEMENT | 1 | HKEx | ||
22.04. | GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: THE GROUP'S FIRST GENERIC FLUTICASONE PROPIONATE NASAL SPRAY IN CHINA APPROVED FOR COMMERCIALIZATION | 2 | HKEx |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
FRESENIUS MEDICAL CARE | 42,340 | +0,67 % | UBS stuft FMC FRESENIUS MEDICAL CARE AG auf 'Sell' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für FMC mit einem Kursziel von 38 Euro auf "Sell" belassen. Analyst Graham Doyle ging am Dienstagnachmittag auf das Feedback... ► Artikel lesen | |
CARL ZEISS MEDITEC | 43,140 | +0,56 % | Aktie von Carl Zeiss Meditec kann Vortagsniveau nicht halten (40,72 €) | Am deutschen Aktienmarkt liegt die Carl Zeiss Meditec-Aktie gegenwärtig im Minus. Der jüngste Kurs betrug 40,72 Euro. Der Anteilsschein von Carl Zeiss Meditec verzeichnet zur Stunde einen Kursrückgang... ► Artikel lesen | |
ECKERT & ZIEGLER | 17,220 | -0,29 % | BERENBERG stuft ECKERT & ZIEGLER auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Bewertung der Aktien von Eckert & Ziegler beim Kursziel von 24 Euro mit "Buy" aufgenommen. Der Medizin- und Messtechnikzulieferer sei der... ► Artikel lesen | |
MEDTRONIC | 79,02 | -0,57 % | Medtronic Prices EUR 1.5 Bln In Senior Notes Due 2030 And 2045 | WASHINGTON (dpa-AFX) - Medtronic plc (MDT) announced that its wholly-owned indirect subsidiary, Medtronic, Inc., has priced an offering of 750 million euros principal amount of 2.950% senior... ► Artikel lesen | |
SERNOVA BIOTHERAPEUTICS | 0,107 | -4,46 % | Sernova Biotherapeutics, Inc.: Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes | LONDON, Ontario, July 09, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics ("Sernova") (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH) today announced a Collaborative Research Agreement with Eledon Pharmaceuticals... ► Artikel lesen | |
FAMICORD | 6,400 | -5,19 % | Original-Research: FamiCord AG (von Montega AG): Halten (zuvor: Kaufen) | Original-Research: FamiCord AG - von Montega AG
03.09.2025 / 10:03 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group.
Für den Inhalt der Mitteilung... ► Artikel lesen | |
GERATHERM MEDICAL | 3,150 | +4,30 % | Geratherm Medical AG: Starkes Wachstum im ersten Halbjahr und operatives Break-even; KAUFEN bestätigt. | Geratherm verzeichnete im ersten Halbjahr 2025 ein starkes Wachstum: Die vergleichbaren Umsätze stiegen um 13,2 % gegenüber dem Vorjahr und sequenziell um 15,4 %. Getrieben wurde dieses Wachstum von... ► Artikel lesen | |
PLUS THERAPEUTICS | 0,413 | 0,00 % | Plus Therapeutics Inc.: Plus Therapeutics Regains Compliance with Applicable Nasdaq Listing Criteria | HOUSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform... ► Artikel lesen | |
ALIGNMENT HEALTHCARE | 16,320 | 0,00 % | Alignment Healthcare, Inc. - 8-K, Current Report | ||
KINDLY MD | 1,240 | 0,00 % | KindlyMD, Inc: KindlyMD Approved for Options Trading on Nasdaq | SALT LAKE CITY, UT / ACCESS Newswire / September 10, 2025 / KindlyMD, Inc. (NASDAQ:NAKA) ("KindlyMD" or "the Company"), a provider of integrated healthcare services and a Bitcoin treasury vehicle via... ► Artikel lesen | |
NANOVIBRONIX | 10,700 | 0,00 % | NanoVibronix files to sell 1.35M shares of common stock for holders | ||
FRESENIUS | 46,940 | +0,17 % | JPMORGAN stuft Fresenius SE auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat Fresenius auf "Overweight" belassen. Die Aktie steht zudem auf der "Analyst Focus List" der US-Bank. Die Aktienkurse der europäischen Medizinunternehmen... ► Artikel lesen | |
BRIGHTSPRING HEALTH SERVICES | 27,180 | 0,00 % | BrightSpring Health: UBS bestätigt Kaufempfehlung angesichts starker Wachstumsaussichten | ||
SIEMENS HEALTHINEERS | 47,750 | -0,13 % | Siemens Healthineers sondiert Verkauf der Diagnostics-Sparte - Agentur | DJ Siemens Healthineers sondiert Verkauf der Diagnostics-Sparte - Agentur
DOW JONES--Siemens Healthineers hat nach Informationen der Nachrichtenagentur Bloomberg Sondierungsgespräche über einen... ► Artikel lesen | |
BETA BIONICS | 25,310 | 0,00 % | Beta Bionics, Inc.: Beta Bionics Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Guidance | IRVINE, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial... ► Artikel lesen |